Date of beginningTuesday, 29 January 2019
MemoThe inaugural Longevity Therapeutics 2019 will bring together the leading biotech drug developers, academics, investors and pharma companies endeavoring to develop innovative therapies targeting age-related conditions.
Join them to collaboratively tackle specific challenges faced to develop these therapies – from discovery, to preclinical activities, translational research, clinical development, regulatory and commercial considerations – and uncover the details behind the latest developments in this space.
Early Rate: USD 1799.0Standard Rate: USD 2099.0
On Tuesday January 29, 2019 at 8:00 am (ends Thursday January 31, 2019 at 5:00 pm)
Speakers: Aubrey de Grey - AgeX Therapeutics, Judith Campisi - Buck Institute for Research on Aging, Nathaniel David - Unity Biotechnology, Nir Barzilai - Albert Einstein College of Medicine, Samuel Agus - Biophytis, Steven Braithwaite - Alkahest Inc., Ronald Kohanski - National Institute on Aging, NIH, Mark Bamberger - Stealth BioTherapeutics, Marc Ramis-Castelltort - Senolytic Therapeutics Inc., Lorna Harries - University of Exeter Medical School, Lindsay Wu - UNSW Sydney, Life Biosciences, Kristen Fortney - BioAge Labs, Kelsey Moody - Antoxerene/Ichor Therapeutics
Venue details: Argonaut Hotel, 495 Jefferson Street, San Francisco, 94109, United States